- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01197690
Association Between Fractional Exhaled Nitric Oxide and Asthma Control (FeNO_AS)
Study Overview
Status
Conditions
Detailed Description
From many previous studies, fractional exhaled nitric oxide (FeNO) has many benefits such as non-invasive, easily to perform, less time consume, has direct association with severity of inflammation of bronchial trees and sputum eosinophils, has benefit for diagnosis and monitoring the treatment in asthmatic patients.
In Thailand, this field of study is less extend, especially in children population. We hypothesized that in uncontrolled or partly controlled group may have high level of fractional exhaled nitric oxide (FeNO) than controlled group.
It is therefore desirable to examine the association between fractional exhaled nitric oxide (FeNO) and level of asthma control among atopic asthmatic Thai children and will be the main objective of this research.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Bangkok, Thailand
- Siriraj Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- clinical diagnosis of atopic bronchial asthma
- follow up in clinic of allergy and clinical immunology, Siriraj hospital
Exclusion Criteria:
- smoker or past history of smoking
- has chronic disease eg. HIV infection, pulmonary hypertension, systemic lupus erythematosus, liver cirrhosis, gastroesophageal reflux, COPD, bronchiectasis
- drink ethanol within 48 hours before enrollment
- history of upper or lower respiratory tract infection within 6 weeks before enrollment
- drink caffeine within day before enrollment
- during pregnancy
- history of systemic steroid use within 8 weeks before enrollment
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
fractional exhaled nitric oxide level
Time Frame: 10 minutes (average time), on the day of enrollment
|
10 minutes (average time), on the day of enrollment
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
scores of asthma control test: ACT
Time Frame: 5 minutes (average time), on the day of enrollment
|
5 minutes (average time), on the day of enrollment
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Professor Nualanong Visitsunthorn, MD, Department of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 602/2552(EC1)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bronchial Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SamA Pharmaceutical Co., LtdCompleted
-
Johann Wolfgang Goethe University HospitalCompleted
-
AstraZenecaRecruitingBronchial Asthma (Only the Patients With Severe or Intractable Bronchial Asthma Which Could Not be Controlled With the Existing Therapy)Japan
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedAsthma, Bronchial | Bronchial AsthmaRussian Federation, Poland, Germany, Ukraine, Czech Republic
-
Astellas Pharma IncAstellas Pharma Europe B.V.CompletedAsthma, Bronchial | Bronchial AsthmaRussian Federation, Hungary, Germany, Poland, Bulgaria, Ukraine, Czech Republic
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Johann Wolfgang Goethe University HospitalWithdrawnAllergy | Allergic Asthma | Intrinsic Asthma | Bronchial HyperresponsivenessGermany